Tocilizumab in management of refractory juvenile idiopathic arthritis, 10 years of experience at tertiary university hospital

被引：0
作者：
Mohammed A. Muzaffer
Abobakr A. Abdelgalil
机构：
[1] King Abdulaziz University,Department of Pediatrics
[2] Cairo University,Department of Pediatrics
来源：
Egyptian Rheumatology and Rehabilitation | 2021年 / 48卷
关键词：
JIA; Tocilizumab; Efficacy; Safety; Biological therapy; JADAS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 174 条
  • [1] Giani T(2020)Association of juvenile idiopathic arthritis and morphea: a case series Clin Rheumatol 39 1341-1345
  • [2] Madera A(2004)International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 J Rheumatol 31 390-392
  • [3] Cimaz R(2016)Management of children with juvenile idiopathic arthritis Indian J Pediatr 83 63-70
  • [4] Petty RE(2015)Treatment in juvenile rheumatoid arthritis and new treatment options Turk Pediatri Ars 50 1-10
  • [5] Southwood TR(2020)Current management of juvenile idiopathic arthritis affecting the craniovertebral junction Childs Nerv Syst 36 1529-1538
  • [6] Manners P(2016)Serum vitamin D levels during activation and remission periods of patients with juvenile idiopathic arthritis and familial Mediterranean fever Turk J Pediatr 58 125-131
  • [7] Baum J(2016)Tocilizumab for treating juvenile idiopathic arthritis Expert Opin Biol Ther 16 559-566
  • [8] Glass DN(2020)Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis Rheumatology (Oxford) 59 732-741
  • [9] Goldenberg J(2017)Biologic agents in the treatment of childhood-onset rheumatic disease J Pediatr 189 31-39
  • [10] He X(2018)Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial Clin Rheumatol 37 1807-1816
12345678910